A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL

Background In lymphoid malignancies, the introduction of chimeric antigen receptor T (CAR-T) cells and bispecific antibodies (bsAbs) has achieved remarkable clinical success. However, such immunotherapeutic strategies are not yet established for acute myeloid leukemia (AML), the most common form of...

Full description

Bibliographic Details
Main Authors: Melanie Märklin, Gundram Jung, Jonas S Heitmann, Joseph Kauer, Helmut R Salih, Stefanie Mueller, Bochong Li, Latifa Zekri, Naveen K Mehta, Martin Pfluegler, Kristan Meetze, Isabelle Sindel, Fabian Vogt, Lukas Osburg, Hans-Jörg Bühring, Sebastian Hörner, Patrick A Baeuerle, Jennifer S Michaelson
Format: Article
Language:English
Published: BMJ Publishing Group 2022-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/3/e003882.full

Internet

https://jitc.bmj.com/content/10/3/e003882.full

Similar Items